美东时间11月11日周一,诺和诺德美股盘中一度涨超2.9%,原因是摩根大通将该公司股票列入“正面催化清单”,并给予“超配”评级。摩根大通的理由是看好诺和诺德即将于12月份披露减肥药CagriSema的研究数据。摩根大通由Richard Vosser领导的分析师团队认为,这些数据将有可能证实CagriSema具有“最佳疾病治疗效果”(best in disease profile),也就是说在所有...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.